Beam Therapeutics Inc (BEAM) — Cash Flow-to-Debt Ratio
Beam Therapeutics Inc (BEAM) has a Cash Flow-to-Debt Ratio of -0.21x as of June 2026, meaning its operating cash flow of $-66.10 Million could theoretically repay 0% of its total liabilities ($319.19 Million) in one year. See BEAM financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Beam Therapeutics Inc Cash Flow-to-Debt Ratio (2017–2025)
Historical debt coverage capacity for Beam Therapeutics Inc across 9 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Beam Therapeutics Inc.
Annual Cash Flow-to-Debt Ratio for Beam Therapeutics Inc (2017–2025)
Year-by-year debt coverage analysis for Beam Therapeutics Inc. Check Beam Therapeutics Inc (BEAM) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.42x | $-345.10 Million | $242.82 Million | ▼ -51.6% |
| 2024 | -0.94x | $-347.25 Million | $370.28 Million | ▼ -200.7% |
| 2023 | -0.31x | $-149.19 Million | $478.38 Million | ▼ -942.1% |
| 2022 | 0.04x | $22.53 Million | $608.24 Million | ▲ +136.2% |
| 2021 | -0.10x | $-66.27 Million | $647.72 Million | ▲ +78.0% |
| 2020 | -0.46x | $-95.74 Million | $206.12 Million | ▲ +64.4% |
| 2019 | -1.31x | $-72.00 Million | $55.15 Million | ▼ -112.1% |
| 2018 | -0.62x | $-20.30 Million | $32.98 Million | ▼ -49.7% |
| 2017 | -0.41x | $-2.71 Million | $6.58 Million | — |